Pharmacoepidemiology and Therapeutic Risk Management

Pharmacoepidemiology and Therapeutic Risk Management
Author :
Publisher :
Total Pages : 0
Release :
ISBN-10 : 0929375300
ISBN-13 : 9780929375304
Rating : 4/5 (304 Downloads)

Book Synopsis Pharmacoepidemiology and Therapeutic Risk Management by : Abraham G. Hartzema

Download or read book Pharmacoepidemiology and Therapeutic Risk Management written by Abraham G. Hartzema and published by . This book was released on 2008 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt:


Pharmacoepidemiology and Therapeutic Risk Management Related Books

Pharmacoepidemiology and Therapeutic Risk Management
Language: en
Pages: 0
Authors: Abraham G. Hartzema
Categories: Drug monitoring
Type: BOOK - Published: 2008 - Publisher:

DOWNLOAD EBOOK

Therapeutic Risk Management of Medicines
Language: en
Pages: 435
Authors: Stephen J. Mayall
Categories: Medical
Type: BOOK - Published: 2014-04-16 - Publisher: Elsevier

DOWNLOAD EBOOK

Therapeutic risk management of medicines is an authoritative and practical guide on developing, implementing and evaluating risk management plans for medicines
Pharmacoepidemiology
Language: en
Pages: 977
Authors: Brian L. Strom
Categories: Medical
Type: BOOK - Published: 2012-03-05 - Publisher: John Wiley & Sons

DOWNLOAD EBOOK

Now in its fifth edition, Pharmacoepidemiology defines the discipline and provides the most comprehensive guidance of any book on the topic. Written by world re
Pharmacoepidemiology
Language: en
Pages: 1220
Authors: Brian L. Strom
Categories: Medical
Type: BOOK - Published: 2019-12-16 - Publisher: John Wiley & Sons

DOWNLOAD EBOOK

This classic, field-defining textbook, now in its sixth edition, provides the most comprehensive guidance available for anyone needing up-to-date information in
Benefit-Risk Assessment in Pharmaceutical Research and Development
Language: en
Pages: 222
Authors: Andreas Sashegyi
Categories: Mathematics
Type: BOOK - Published: 2013-11-27 - Publisher: CRC Press

DOWNLOAD EBOOK

Many practitioners in the pharmaceutical industry are still largely unfamiliar with benefit-risk assessment, despite its growing prominence in drug development